GeneNews Partners with Enzo Clinical Labs to Market ColonSentry™ in the U.S.
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
GeneNews Limited has announced that it has entered into a marketing partnership agreement with Enzo Clinical Labs for the exclusive rights to market ColonSentry, which is said to be the world’s first blood test for colorectal cancer, in New York and New Jersey.
Enzo will validate and seek approval of the ColonSentry test pursuant to New York, New Jersey and CLIA requirements in addition to marketing and securing third party reimbursement for the test. Commercial terms were not disclosed. Enzo is projecting the U.S. launch of ColonSentry in the second half of 2010.
“Enzo is focused on bringing leading edge, world-class molecular tests to our customers and offering first-in-class tests such as ColonSentry is a central component of this strategy,” said Dr. Kevin Krenitsky, President of Enzo Clinical Labs. “We are pleased to be working with GeneNews as their exclusive marketing partner in our key territories for this groundbreaking test which offers patients a novel, non-invasive option for determining an individual’s current risk for colorectal cancer.”
“The greatest barrier to reducing mortality arising from colorectal cancer is patient compliance with screening,” said Dr. Bernard Levin, an internationally recognized expert in colorectal cancer screening and Chair of the GeneNews Colorectal Cancer Clinical Advisory Board. “As a blood-based test, ColonSentry can encourage individuals to undergo screening which could lead to earlier detection, thereby potentially reducing the suffering and death that can result from this highly treatable disease.”
“GeneNews is pleased to be working with Enzo, an undisputed leader in the molecular diagnostic lab space and an excellent match for our lead product,” said Dr. Heiner Dreismann, Lead Director and Interim CEO of GeneNews. “Enzo is our first US regional marketing partner and will provide an important segment of the eligible U.S. population with access to our ColonSentry test,” added Gailina Liew, COO of GeneNews.
Enzo will validate and seek approval of the ColonSentry test pursuant to New York, New Jersey and CLIA requirements in addition to marketing and securing third party reimbursement for the test. Commercial terms were not disclosed. Enzo is projecting the U.S. launch of ColonSentry in the second half of 2010.
“Enzo is focused on bringing leading edge, world-class molecular tests to our customers and offering first-in-class tests such as ColonSentry is a central component of this strategy,” said Dr. Kevin Krenitsky, President of Enzo Clinical Labs. “We are pleased to be working with GeneNews as their exclusive marketing partner in our key territories for this groundbreaking test which offers patients a novel, non-invasive option for determining an individual’s current risk for colorectal cancer.”
“The greatest barrier to reducing mortality arising from colorectal cancer is patient compliance with screening,” said Dr. Bernard Levin, an internationally recognized expert in colorectal cancer screening and Chair of the GeneNews Colorectal Cancer Clinical Advisory Board. “As a blood-based test, ColonSentry can encourage individuals to undergo screening which could lead to earlier detection, thereby potentially reducing the suffering and death that can result from this highly treatable disease.”
“GeneNews is pleased to be working with Enzo, an undisputed leader in the molecular diagnostic lab space and an excellent match for our lead product,” said Dr. Heiner Dreismann, Lead Director and Interim CEO of GeneNews. “Enzo is our first US regional marketing partner and will provide an important segment of the eligible U.S. population with access to our ColonSentry test,” added Gailina Liew, COO of GeneNews.
